Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Rinvoq (upadacitinib) and Actemra (tocilizumab) are both medications used to treat inflammatory conditions like rheumatoid arthritis (RA). However, they belong to different medication classes. Rinvoq is a Janus kinase (JAK) inhibitor, while Actemra is an interleukin-6 (IL-6) receptor antagonist. Rinvoq is taken orally, either as an extended-release tablet or an oral solution, and is typically dosed once daily. In contrast, Actemra is administered via injection, either intravenously or subcutaneously, with dosing intervals ranging from weekly to monthly. Rinvoq is available only as a brand-name medication, whereas Actemra has a biosimilar option called Tofidence. Common side effects of Rinvoq include a higher risk of infections, acne, and nausea, while Actemra can cause upper respiratory tract infections, headaches, and high blood pressure. Both medications can increase the risk of infections due to their immunosuppressive effects, but they have different interactions and precautions. For example, Rinvoq should not be taken with grapefruit, and Actemra requires careful monitoring of liver function.
Rinvoq (upadacitinib)
Actemra (tocilizumab)
Rinvoq (upadacitinib)
Actemra (tocilizumab)
Summary of Rinvoq vs. Actemra
Summary for JAK inhibitor
Prescription only
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.
Summary for IL-6 receptor antagonist
Prescription only
Actemra (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist. It treats several inflammatory conditions in children and adults, including rheumatoid arthritis. It works by blocking IL-6, a chemical released by the immune system that causes inflammation and fever. Actemra (tocilizumab) is given as an injection (either through the veins or under the skin), typically weekly or every few weeks, depending on the condition you're taking it treat. Side effects include a higher risk of infections and headache.
Indications of Rinvoq vs. Actemra
Indications for
Moderate-to-severe inflammatory conditions in which other treatments haven't worked: